Showing Latest Articles
Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study
Diabetes, Obesity and Metabolism, 01/11/2012
Clinical Article
Lazich I et al. – This data show that patients with the metabolic syndrome given a statin/thiazolidinediones (TZDs) combination manifest greater reductions in markers of vascular inflammation and oxidant stress, 24–h ambulatory blood pressure (BP) and increases in adiponectin as well as improved glycaemic indices.
Methods- This is a randomized, double blind, placebo–controlled study in 53 subjects with the metabolic syndrome.
- Participants were randomized to simvastatin 40 mg/day plus placebo vs. simvastatin 40 mg/day plus rosiglitazone 4 mg/day for 6 months.
- The primary endpoint was the between–group difference in high–sensitivity C–reactive protein (hs–CRP) and secondary variables including urinary isoprostanes, serum malondialdehyde (MDA), ambulatory BP, adiponectin, and lipid and glycaemic profiles.
- At study end, the group randomized to the simvastatin/rosiglitazone combination had a greater reduction in hs–CRP of 1.33 mg/dl, (p = 0.029) and showed a trend for a greater reduction in urinary isoprostane (–39%), (p = 0.056) compared to simvastatin/placebo group.
- Changes in MDA levels did not differed between groups (p = 0.81).
- 24–h systolic blood pressure (SBP) also showed a 4.5 mmHg reduction at 6 months (p = 0.06).
- Adiponectin levels increased by 3.91 μg/ml in the combination group over placebo, (p = 0.03) and blood glucose decreased in combination group vs. placebo.
